Organization
Mayo Clinic College of Medicine and Science, Scottsdale, AZ
4 abstracts
Abstract
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).Org: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, Ziauddin Medical University, Karachi, Pakistan, Canyon Vista Medical Center, Sierra Vista, AZ, University of Arizona, Tucson, AZ, Rashid Latif Medical College, Lahore, Pakistan,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.Org: Lantern Pharma, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, Brown University Warren Alpert Medical School, Winship Cancer Institute of Emory University, DTC,
Abstract
ANALYSES OF PLASMA METABOLIC PROTEINS REVEAL BIOMARKERS PREDICTIVE OF SUBSEQUENT DEVELOPMENT OF GIANT CELL ARTERITIS; A PROSPECTIVE STUDYOrg: Lund University, Academic Specialist Center, Center for Rheumatology, Stockholm, Sweden, University of Gothenburg, Skåne University Hospital, Lund University, University of Cambridge,